Dr. Peter Winkle

Gastroenterology
Associated Gastroenterology Medical Group
1211 W La Palma Ave Ste 306, 
Anaheim, CA 
Associated Gastroenterology Medical Group
1211 W La Palma Ave Ste 306, 
Anaheim, CA 

Overview

Peter Winkle is a Gastroenterologist in Anaheim, California. His top areas of expertise are Celiac Disease, Malabsorption, Plaque Psoriasis, Chronic Idiopathic Constipation (CIC), and Osteotomy.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
View 3 Less Insurance Carriers -

Locations

Associated Gastroenterology Medical Group
1211 W La Palma Ave Ste 306, Anaheim, CA 92801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers
A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Randomized Study to Evaluate the Bioequivalence of Selpercatinib Formulations
An Open-Label, Randomized Study to Evaluate the Bioequivalence of Selpercatinib Formulations
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3509754 in Healthy Non-Japanese and Japanese Participants
A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3509754 in Healthy Non-Japanese and Japanese Participants
Enrollment Status: Terminated
Publish Date: January 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
Enrollment Status: Completed
Publish Date: August 06, 2024
Intervention Type: Drug
Study Drug: KAN-101
Study Phase: Phase 1
Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: January 29, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB122 in Healthy Adult Japanese, Chinese, and Caucasian Participants
An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB122 in Healthy Adult Japanese, Chinese, and Caucasian Participants
Enrollment Status: Completed
Publish Date: April 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Four-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Gluten Degradation Activity of PvP001, PvP002, and PvP003 in Healthy Adult Volunteers and to Assess the Safety, Tolerability, and Pharmacokinetics of PvP001 and PvP002 in Adults With Celiac Disease
A Phase 1, Four-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Gluten Degradation Activity of PvP001, PvP002, and PvP003 in Healthy Adult Volunteers and to Assess the Safety, Tolerability, and Pharmacokinetics of PvP001 and PvP002 in Adults With Celiac Disease
Enrollment Status: Completed
Publish Date: April 04, 2023
Intervention Type: Drug, Other
Study Phase: Phase 1
A Randomized, Double-blind, Single Ascending Dose Study to Determine the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3772847 Administered Subcutaneously in Healthy Participants
A Randomized, Double-blind, Single Ascending Dose Study to Determine the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3772847 Administered Subcutaneously in Healthy Participants
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
Study 0146: A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of TD-3504 in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
Study 0146: A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of TD-3504 in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
Enrollment Status: Completed
Publish Date: January 14, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Open Label, Multi-center, Parallel Cohort, Single Dose Study to Evaluate the Pharmacokinetics of LEE011 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.
A Phase I, Open Label, Multi-center, Parallel Cohort, Single Dose Study to Evaluate the Pharmacokinetics of LEE011 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 1
AMPOWER A Single-arm, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of Phexxi™ (Previously Referred to as AMPHORA®) Contraceptive Vaginal Gel
AMPOWER A Single-arm, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of Phexxi™ (Previously Referred to as AMPHORA®) Contraceptive Vaginal Gel
Enrollment Status: Completed
Publish Date: September 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A PHASE 1, WITHIN COHORT, RANDOMIZED, DOUBLE BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06826647 IN HEALTHY SUBJECTS AND SUBJECTS WITH PLAQUE PSORIASIS
A PHASE 1, WITHIN COHORT, RANDOMIZED, DOUBLE BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06826647 IN HEALTHY SUBJECTS AND SUBJECTS WITH PLAQUE PSORIASIS
Enrollment Status: Completed
Publish Date: March 31, 2020
Intervention Type: Drug, Other
Study Phase: Phase 1
A Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Japanese and Caucasian Healthy Subjects
A Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Japanese and Caucasian Healthy Subjects
Enrollment Status: Completed
Publish Date: May 03, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Randomized, Blinded, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
A Phase 1, Randomized, Blinded, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
Enrollment Status: Completed
Publish Date: April 16, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 14 Less Clinical Trials

35 Total Publications

Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain.
Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain.
Journal: Journal of pain research
Published: December 08, 2024
Similar Doctors
Expertise in
53
conditions
Dr. Jason Samarasena
Gastroenterology
Expertise in
53
conditions
Dr. Jason Samarasena
Gastroenterology

UCI Health H.H. Chao Comprehensive Digestive Disease Center

101 The City Dr S Bldg 22C, 
Orange, CA 
 (8.8 miles away)
888-717-4463
Languages Spoken:
English
See accepted insurances

Jason Samarasena is a Gastroenterologist in Orange, California. Dr. Samarasena is highly rated in 53 conditions, according to our data. His top areas of expertise are Barrett Esophagus, Jaundice, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Colonoscopy.

Expertise in
21
conditions
Dr. Norah Terrault
Gastroenterology
Expertise in
21
conditions
Dr. Norah Terrault
Gastroenterology

Los Angeles-Gi Liver Clinic

1510 San Pablo St Ste 200, 
Los Angeles, CA 
 (20.7 miles away)
323-442-8894
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Norah Terrault is a Gastroenterologist in Los Angeles, California. Dr. Terrault is highly rated in 21 conditions, according to our data. Her top areas of expertise are Hepatitis, Hepatitis C, Hepatitis B, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

Expertise in
43
conditions
Dr. James Buxbaum
Gastroenterology
Expertise in
43
conditions
Dr. James Buxbaum
Gastroenterology

USC University Hospital

1520 San Pablo St Ste 1000, 
Los Angeles, CA 
 (20.7 miles away)
323-442-5100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Buxbaum is a Gastroenterologist in Los Angeles, California. Dr. Buxbaum is highly rated in 43 conditions, according to our data. His top areas of expertise are Acute Pancreatitis, Hereditary Pancreatitis, Choledocholithiasis, Endoscopy, and Lithotripsy.

Frequently Asked Questions about Dr. Peter Winkle

How do I make an appointment with Dr. Peter Winkle?

You can book an appointment with Dr. Peter Winkle by calling their office at 714-633-1823. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Peter Winkle a top-rated expert for Osteotomy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Peter Winkle is classified as an Experienced expert for Osteotomy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Peter Winkle specialize in?

While Dr. Peter Winkle is a Gastroenterology, they have specific expertise in Osteotomy, Celiac Disease, and Malabsorption. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Peter Winkle participate in research or clinical trials?

Yes. Dr. Peter Winkle has published 35 articles and abstracts on conditions like Osteotomy. You can view a list of Dr. Peter Winkle's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Peter Winkle accept my insurance?

Dr. Peter Winkle accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 714-633-1823 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Winkle's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile